In a separate study comprised of 64 cases, EZH2 protein expression levels independently predicted worse recurrence-free survival and outperformed other known prognostic factors, such as Gleason score, tumor size and preoperative prostate-specific antigen (PSA) levels [19]. This evidence concerns the gene KLK3 and neoplasm.